Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors inside the central nervous technique, conolidine modulates alternate molecular targets. A Science Innovations review located that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://robertb119lwh5.wikibyby.com/user